Table 1.
Baseline clinical characteristics across kidney function groups
| eGFR ≥60 mL/min/1.73 m2 (n = 401) | eGFR <60 mL/min/1.73 m2 (n = 160) | P-value | |
|---|---|---|---|
| Age, years | 60 ± 11 | 69 ± 9 | <0.01 |
| Men (%) | 310 (77) | 130 (81) | 0.31 |
| White, n (%) | 360 (90) | 150 (94) | 0.14 |
| NYHA class II, n (%) | 327 (82) | 130 (81) | 0.94 |
| Ischaemic CM, n (%) | 201 (50) | 120 (75) | <0.01 |
| Diabetes, n (%) | 79 (20) | 52 (33) | <0.01 |
| Hypertension, n (%) | 203 (51) | 98 (61) | 0.02 |
| ACE-I, n (%) | 323 (81) | 113 (71) | 0.01 |
| ARBs, n (%) | 80 (20) | 41 (26) | 0.14 |
| Beta-blockers, n (%) | 384 (96) | 148 (93) | 0.12 |
| Diuretics, n (%) | 309 (77) | 140 (88) | <0.01 |
| Intrinsic QRS duration, mean ± SD, ms | 153 ± 22 | 153 ± 22 | 0.97 |
| Left ventricular | |||
| Ejection fraction, % | 26 ± 7 | 28 ± 7 | 0.02 |
| End-diastolic diameter, cm | 6.9 ± 1.0 | 6.8 ± 0.8 | 0.37 |
| End-systolic diameter, cm | 5.8 ± 1.1 | 5.6 ± 0.9 | 0.22 |
| End-systolic volume, mL | 205 ± 85 | 188 ± 64 | 0.02 |
| End-diastolic volume, mL | 276 ± 99 | 258 ± 77 | 0.05 |
| Mass, g | 273 ± 79 | 273 ± 74 | 0.92 |
| IVMD, ms | 36 ± 41 | 26 ± 35 | 0.01 |
| Heart rate, mean ± SD, b.p.m. | 68 ± 11 | 66 ± 10 | 0.05 |
| Supine blood pressure, mean ± SD, mmHg | |||
| Systolic | 125 ± 18 | 125 ± 20 | 0.90 |
| Diastolic | 73 ± 11 | 70 ± 11 | <0.01 |
| Weight, kg | 88 (19) | 84 (17) | 0.05 |
| K+, mean ± SD, mmol/dL | 4.31 ± 0.43 | 4.52 ± 0.50 | <0.01 |
| CRT status, n (%) | 0.66 | ||
| Off | 128 (32) | 48 (30) | |
| On | 273 (68) | 112 (70) | |
ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CM, cardiomyopathy; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; IVMD, interventricular mechanical delay; NYHA, New York Heart Association.